Log In
Tuesday 25th October 2016

NICE approves Lucentis for NHS use

3rd January 2013

Lucentis has been approved for use in the NHS by the National Institute of Health and Clinical Excellence (NICE).


They have given approval for the health service to use the drug, also known as Ranibizumab, in the case of treating a disorder in diabetic patients known as diabetic macular odema.

The makers of the drug, Novartis, made an offer to the NHS to discount the medication, which usually costs about £700 a month to treat one person.

It is administered by an injection into the eye and prevents leaked fluid collecting there.

Professor Carole Longson, Health Technology Evaluation Centre Director at NICE, said: Nice is pleased to recommend ranibizumab as a treatment option for some people with visual impairment caused by diabetic macular oedema in new draft guidance."

She explained that in November last year, NICE had "published guidance which did not recommend the drug as an effective use of NHS resources. However, following the submission of a revised patient access scheme, we have conducted a rapid review of the original guidance."

"The manufacturer also included updated analyses showing that ranibizumab could be expected to have a superior relative effect among people with central retinal thickness greater than 400 micrometres."

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016